Celldex: Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J. , March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4 th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11 th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc. Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com. Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 scavanaugh@celldex.com Patrick Till Meru Advisors (484) 788-8560 ptill@meruadvisors.com Source: Celldex Therapeutics, Inc. 2025 GlobeNewswire, Inc., source Press Releases HAMPTON, N.J. , March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4 th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11 th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc. Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com. Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 scavanaugh@celldex.com Patrick Till Meru Advisors (484) 788-8560 ptill@meruadvisors.com 2025 GlobeNewswire, Inc., source Press Releases